Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Placebo C is an inactive control substance used in a Phase 2a randomized, double-blind, placebo-controlled factorial trial conducted at the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) in Lucknow, India. The trial was designed to evaluate the safety and efficacy of artesunate and curcumin in patients with mild to moderate Crohn's disease who had ongoing disease activity despite azathioprine therapy. Specifically, Placebo C was formulated to match the appearance and administration of curcumin (2 grams daily) to maintain the study's blinding. The placebo was provided by Cadila Pharmaceuticals India, and the study was supported by Bowel Disease UK.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Placebo C-Sanjay Gandhi Postgraduate Institute of Medical Sciences-Crohn's disease.